Back to Results

Protocol MK-5475-007: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Primary Objective

Phase 2 cohort: To evaluate the effect of MK-4575 versus placebo on pulmonary vascular resistance from baseline to week 12. Phase 3 Cohort: To evaluate the effects of MK-5475 versus placebo on 6 minute walk test distances from baseline to week 12.

Study category: Heart and Blood Conditions

Is this Study for You?

Let's Get Started!



Type of Study





Outpatient CTRC
University of Colorado Hospital

Principal Investigator
David Badesch,  MD

David Badesch, MD

Study ID

Protocol Number: 21-2564

More information available at NCT04732221

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers